The PPTC is funded through a cooperative agreement, and NCI has specific responsibilities in providing scientific and technical and regulatory assistance, advice, and coordination within the Consortium. The NCI Program Director for the PPTC is Dr. Malcolm Smith of the Cancer Therapy Evaluation Program (CTEP), and Dr. Beverly Teicher serves as an NCI Steering Committee representative. NCI is responsible for negotiating Material Transfer Agreements (MTAs) with pharmaceutical companies, with Drs. Jian Zhang and Sherry Ansher of the Regulatory Affairs Branch (CTEP, NCI) taking the lead in negotiating these MTAs that allow agents to be tested through the NCI PPTC.
Dr. Smith is Associate Branch Chief, Pediatrics in the Clinical Investigations Branch [Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI)]. Dr. Smith has been a member of CTEP since 1990 and during his years at CTEP has focused on developing NCI's preclinical and clinical research programs for children with cancer. Dr. Smith serves as an NCI liaison to childhood cancer investigators in the Children's Oncology Group, focusing primarily on hematologic malignancies and brain cancers. He also serves as the Program Director for the Children's Oncology Group Phase 1/Pilot Consortium and serves as the NCI Program Director for the Pediatric Brain Tumor Consortium. He served as the Project Officer for the Pediatric Preclinical Testing Program (PPTP), the predecessor to the PPTC.
Dr. Beverly A. Teicher, PhD is Chief of the Molecular Pharmacology Branch at NCI, a position that she assumed in 2011. One focus of the Molecular Pharmacology Branch is target and drug discovery for rare and recalcitrant cancers such as sarcoma and small cell lung cancer. Prior to joining NCI, Dr. Teicher was at Genzyme Corporation for 9 years where she was Vice President of Oncology Research, and prior to that she was at Lilly Research Laboratories and the Dana-Farber Cancer Institute. Dr. Teicher is an active member of the international scientific community having authored or co-authored >400 scientific publications. She has edited eight books, is senior editor for the journal Clinical Cancer Research, executive editor of the journal Pharmacology and Therapeutics and is series editor for the Cancer Drug Discovery and Development book series of >70 volumes.